Benzene, Pyridine, and Pyridazine Derivatives
Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein A, Q 1 , Q 2 , Q 3 , R 3 , R 4 , R 5 , R O , m, and p are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.
1 . A compound of the formula
or a pharmaceutically acceptable salt thereof, wherein
p is 0, 1, 2, 3, 4, or 5;
m is 0, 1, 2, 3, 4, or 5, provided that the sum of m and p is less than or equal to 5;
each q is independently 0, 1, or 2;
each R is independently halogen, cyano, nitro, C 1 -C 6 alkyl, halo(C 1 -C 6 )alkyl, hydroxy, C 1 -C 6 alkoxy, halo(C 1 -C 6 )alkoxy, amino, mono- or di-(C 1 -C 6 ) alkylamino, carboxy, carboxamide, C 3 -C 7 cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
each R C is independently halogen, cyano, nitro, —OR O , —N(R N ) 2 , SR O , or —R N ;
each R N is independently —R N′ , —C(O)R N′ , —C(O)OR N′ , —C(O)N(R N′ ) 2 , —S(O)R N′ , or —S(O) 2 R N′ wherein
each R N′ is independently hydrogen, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 1 -C 10 haloalkyl, C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkyl (C 1 -C 10 )alkyl, heterocycloalkyl, heterocycloalkyl (C 1 -C 10 )alkyl, aryl, aryl (C 1 -C 10 )alkyl, heteroaryl, or heteroaryl(C 1 -C 10 )alkyl, wherein
each R N′ is optionally substituted with from 1 to 4 R groups;
each R O is independently —R N′ , —C(O)R N′ , —C(O)OR N′ , or —C(O)N(R N′ ) 2 ;
R 3 and R 4 are independently (a) hydrogen, (b) halo, or (c) a C 1 -C 15 alkyl group where up to six of the carbon atoms in said alkyl group are optionally replaced independently by R 22 , carbonyl, ethenyl, ethynyl or a moiety selected from N, O, or S(O) q , with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other, wherein
each R 22 is independently (i) heteroaryl, (ii) aryl, (iii) saturated or unsaturated C 3 -C 10 cycloalkyl, or (iv) saturated or unsaturated C 2 -C 10 heterocycloalkyl, wherein
each R 22 is optionally substituted with 1 to 4 groups which are independently —R, oxo, —SH, —S(O) q —(C 1 -C 6 )alkyl, —S(O) q -aryl, —SO 2 NH 2 , —SO 2 NH—(C 1 -C 6 )alkyl, or —SO 2 NH-aryl; and
each R 22 is optionally fused to a C 6 -C 10 aryl group, C 5 -C 8 saturated cyclic group, or a C 5 -C 10 heterocycloalkyl group; and
each (c) is optionally substituted with —R C , —OR 15 , —SR 15 , or —N(R 15 ) 2 , or —R 22 , wherein
each R 15 is independently —H, (C 1 -C 10 )alkyl, (C 1 -C 10 ) haloalkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, or (C 1 -C 10 )alkyl-Z, wherein
Z is —OR 0 or —N(R 30 ) 2 , wherein
each R 30 is independently —H or C 1 -C 6 alkyl; or N(R 30 ) 2 represents pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, 1,3- or 1,4-diazepanyl, or morpholinyl, each of which is optionally substituted with R; and
or R 3 and R 4 together with the atoms to which they are attached form a 5-12 membered mono-, bi-, or tricyclic ring system fused to the ring containing Q 1 and Q 2 , where the 5-12 membered ring is partially unsaturated or aromatic and optionally contains one or two of oxygen, S(O) q , nitrogen, or NR 33 where R 33 is hydrogen or C 1 -C 6 alkyl;
Q 1 , Q 2 , and Q 3 are independently N or CR Q , with the proviso that at least one Q 1 , Q 2 , or Q 3 is CR Q , wherein
each R Q is independently hydrogen, halogen, —N(R N ) 2 , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 7 cycloalkyl, aryl, or heteroaryl, or —R 21 , wherein each R Q is optionally substituted with from 1-4 R groups, wherein
R 21 is cyano, —C(O)OH, —C(O)—O(C 1 -C 6 alkyl), —C(X)N(R 1 ) 2 , wherein
each R 1 is independently hydrogen, hydroxy, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, heteroaryl, aryl, C 3 -C 8 cycloalkyl, heterocycloalkyl,
wherein each R 1 is optionally substituted with from 1-4 R groups;
or both R 1 together with the nitrogen to which they are attached, form a heterocycloalkyl; and
X is ═O, ═S, ═NH, ═NOH, ═N—NH 2 , ═N—NH-aryl, ═N-=NH— (C 1 -C 6 alkyl), or ═N—(C 1 -C 6 alkoxy);
A is a bond, O, S(O) q , N(R N ), C(O), or CH(R C );
and each R 5 is independently R C .
2 . A compound according to claim 1 , wherein
R 3 and R 4 are independently hydrogen, halo, or -Z 1 R Z1 , wherein Z 1 is —O— or —NH—; and R Z1 is a C 1 -C 14 alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R 22 , carbonyl, ethenyl, ethynyl or a moiety selected from N, O, or S(O) q , with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,
wherein R Z1 is optionally substituted at any available position with R, oxo, R 22 , C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, —SH, —S— (C 1 -C 6 ) alkyl, —SO 2 — (C 1 -C 6 )alkyl, —SO 2 NH 2 , —SO 2 NH-(C 1 -C 6 )alkyl, —SO 2 NH-aryl, —SO 2 -aryl, —SO— (C 1 -C 6 )alkyl, —SO 2 -aryl, or —OC 1 -C 10 alkyl-Z.
3 . A compound according to claim 2 , wherein
R 3 and R 4 are independently hydrogen, halo, or —N(H)R Z1 , wherein R Z1 is a C 1 -C 14 alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R 22 , carbonyl, ethenyl, ethynyl or a moiety selected from N, O, or S(O) q , with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,
wherein R Z1 is optionally substituted at any available position with R, R 22 , oxo, or —OC 1 -C 10 alkyl-Z.
4 . A compound according to claim 1 , wherein
R 21 is cyano.
5 . A compound according to claim 1 , wherein
R 21 is —C(O)N(R 1 ) 2 , wherein each R 1 is independently H, hydroxy, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, heteroaryl, aryl, C 3 -C 8 cycloalkyl, heterocycloalkyl, wherein each R 1 is optionally substituted with from 1 to 4 R groups.
6 . A compound according to claim 5 , wherein
R 21 is —C(O)NH 2 .
7 . A compound according to claim 1 , wherein
Q 1 and Q 2 are CH and Q 3 is CR 21 , wherein R 21 is cyano.
8 . A compound according to claim 1 , wherein Q 1 and Q 2 are CH and Q 3 is CR 21 , wherein R 21 is —C(O)NH 2 .
9 . A compound according to claim 1 , wherein
A is —S—, —NH—, —CH 2 —, or —CH(COOR)—, wherein R is —H or C 1 -C 6 alkyl.
10 . A compound according to claim 1 , wherein
m is 0; and
p is 2 or 3.
11 . A compound according to claim 1 , of the formula,
12 . A compound according to claim 11 , wherein
R 3 and R 4 are independently hydrogen, halo, or -Z 1 R Z1 , wherein Z 1 is —O— or —NH—; and R Z1 is a C 1 -C 14 alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R 22 , carbonyl, ethenyl, ethynyl or a moiety selected from N, O, or S(O) q , with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,
wherein R Z1 is optionally substituted at any available position with R, oxo, R 22 , C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, —SH, —S— (C 1 -C 6 )alkyl, —SO 2 — (C 1 -C 6 )alkyl, —SO 2 NH 2 , —SO 2 NH—(C 1 -C 6 )alkyl, —SO 2 NH-aryl, —SO 2 -aryl, —SO— (C 1 -C 6 )alkyl, —SO 2 -aryl, or —OC 1 -C 10 alkyl-Z.
13 . A compound according to claim 12 , wherein
R 3 and R 4 are independently hydrogen, halo, or —N(H)R Z1 , wherein R Z1 is a C 1 -C 14 alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R 22 , carbonyl, ethenyl, ethynyl or a moiety selected from N, O, or S(O) q , with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,
wherein R Z1 is optionally substituted at any available position with R, R 22 , oxo, or —OC 1 -C 10 alkyl-Z.
14 . A compound according to claim 11 , wherein
R 21 is cyano.
15 . A compound according to claim 11 , wherein
R 21 is —C(O)N(R 1 ) 2 , wherein
each R 1 is independently H, hydroxy, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, heteroaryl, aryl, C 3 -C 8 cycloalkyl, heterocycloalkyl, wherein each R 1 is optionally substituted with from 1 to 4 R groups.
16 . A compound according to claim 15 , wherein
R 21 is —C(O)NH 2 .
17 . A compound according to claim 11 , wherein
A is —S—, —NH—, —CH 2 —, or —CH(COOR)—, wherein
R is —H or C 1 -C 6 alkyl.
18 . A compound according to claim 11 , wherein
m is 0; and
p is 2 or 3.
19 . A compound according to claim 1 , of the formula,
wherein,
R Z1 is a C 1 -C 14 alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R 22 , carbonyl, ethenyl, ethynyl or a moiety selected from N, O, or S(O) q , with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,
wherein R Z1 is optionally substituted at any available position with R, R 22 , oxo, or —OC 1 -C 10 alkyl-Z.
20 . A compound according to claim 19 , wherein
R 21 is cyano.
21 . A compound according to claim 19 , wherein
R 21 is —C(O)N(R 1 ) 2 , wherein
each R 1 is independently H, hydroxy, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, heteroaryl, aryl, C 3 -C 8 cycloalkyl, heterocycloalkyl, wherein each R 1 is optionally substituted with from 1 to 4 R groups.
22 . A compound according to claim 19 , wherein
R 21 is —C(O)NH 2 .
23 . A compound according to claim 19 , wherein
A is —S—, —NH—, —CH 2 —, or —CH(COOR)—, wherein
R is —H or C 1 -C 6 alkyl.
24 . A compound according to claim 19 wherein
m is 0; and
p is 2 or 3.
25 . A compound according to claim 1 , of the formula,
wherein
R Z1 is a C 1 -C 14 alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R 22 , carbonyl, ethenyl, ethynyl or a moiety selected from N, O, or S(O) q , with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,
wherein R Z1 is optionally substituted at any available position with R, R 22 , oxo, or —OC 1 -C 10 alkyl-Z.
26 . A compound according to claim 25 , wherein
R 21 is cyano.
27 . A compound according to claim 25 , wherein
R 21 is —C(O)N(R 1 ) 2 , wherein
each R 1 is independently H, hydroxy, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, heteroaryl, aryl, C 3 -C 8 cycloalkyl, heterocycloalkyl, wherein each R 1 is optionally substituted with from 1 to 4 R groups.
28 . A compound according to claim 25 , wherein
R 21 is —C(O)NH 2 .
29 . A compound according to claim 25 wherein
m is 0; and
p is 2 or 3.
30 . A compound according to claim 1 , of the formula,
wherein
R Z1 is a C 1 -C 14 alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R 22 , carbonyl, ethenyl, ethynyl or a moiety selected from N, O, or S(O) q , with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,
wherein R Z1 is optionally substituted at any available position with R, R 22 , oxo, or —OC 1 -C 10 alkyl-Z.
31 . A compound according to claim 30 , wherein
R 21 is cyano.
32 . A compound according to claim 30 , wherein
R 21 is —C(O)N(R 1 ) 2 , wherein
each R 1 is independently H, hydroxy, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, heteroaryl, aryl, C 3 -C 8 cycloalkyl, heterocycloalkyl, wherein each R 1 is optionally substituted with from 1 to 4 R groups.
33 . A compound according to claim 30 , wherein
R 21 is —C(O)NH 2 .
34 . A compound according to claim 30 , wherein
m is 0; and
p is 2 or 3.
35 . A compound according to claim 1 , of the formula,
wherein
R Z1 is a C 1 -C 14 alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R 22 , carbonyl, ethenyl, ethynyl or a moiety selected from N, O, or S(O) q , with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,
wherein R Z1 is optionally substituted at any available position with R, R 22 , oxo, or —OC 1 -C 10 alkyl-Z.
and R is —H or —COOR′,
wherein R′ is H or C 1 -C 6 alkyl.
36 . A compound according to claim 35 , wherein
R 21 is cyano.
37 . A compound according to claim 35 , wherein
R 21 is —C(O)N(R 1 ) 2 , wherein
each R 1 is independently H, hydroxy, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, heteroaryl, aryl, C 3 -C 8 cycloalkyl, heterocycloalkyl, wherein each R 1 is optionally substituted with from 1 to 4 R groups.
38 . A compound according to claim 35 , wherein
R 21 is —C(O)NH 2 .
39 . A compound according to claim 35 , wherein
m is 0; and
p is 2 or 3.
40 . A compound according to claim 35 , wherein R is —H.
41 . A compound according to claim 35 , wherein
R is —COOR′, wherein R′ is H or C 1 -C 6 alkyl.
42 . A compound according to claim 1 , of the formula,
wherein R Z1 is a C 1 -C 14 alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R 22 , carbonyl, ethenyl, ethynyl or a moiety selected from N, O, or S(O) q , with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,
wherein R Z1 is optionally substituted at any available position with R, R 22 , oxo, or —OC 1 -C 10 alkyl-Z.
43 . A compound according to claim 42 , wherein R 21 is cyano.
44 . A compound according to claim 42 , wherein
R 21 is —C(O)N(R 1 ) 2 , wherein
each R 1 is independently H, hydroxy, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, heteroaryl, aryl, C 3 -C 8 cycloalkyl, heterocycloalkyl, wherein each R 1 is optionally substituted with from 1 to 4 R groups.
45 . A compound according to claim 44 , wherein
R 21 is —C(O)NH 2 .
46 . A compound according to claim 42 , wherein
m is 0 and p is 2 or 3.
47 . A compound according to claim 1 , which is
4-(2,3-Dimethoxyphenyl)-2-(4-hydroxylcyclohexylamino)benzonitrile;
4-(2,3-Dimethoxyphenyl)-2-(4-hydroxylcyclohexylamino)benzamide;
4-(3,4-Dimethoxyphenyl)-2-(4-hydroxylcyclohexylamino)benzonitrile;
4-(3,4-Dimethoxyphenyl)-2-(4-hydroxylcyclohexylamino)benzamide;
3-(4-Hydroxy-cyclohexylamino)-3′-methanesulfonyl-biphenyl-4-carbonitrile;
3-(4-Hydroxy-cyclohexylamino)-3′-methanesulfonyl-biphenyl-4-carboxylic acid amide;
4-(2,5-Dimethoxy-phenylsulfanyl)-2-(4-hydroxy-cyclohexylamino)-benzonitrile;
4-(2,5-Dimethoxy-phenylsulfanyl)-2-(4-hydroxy-cyclohexylamino)-benzamide;
(3-Bromo-4-cyano-phenyl)-(3,4,5-trimethoxy-phenyl)-acetic acid methyl ester;
[4-Cyano-3-(4-hydroxy-cyclohexylamino)-phenyl]-(3,4,5-trimethoxy-phenyl)-acetic acid methyl ester;
[4-Cyano-3-(4-hydroxy-cyclohexylamino)-phenyl]-(3,4,5-trimethoxy-phenyl)-acetic acid;
2-(4-Hydroxy-cyclohexylamino)-4-(3,4,5-trimethoxy-benzyl)-benzamide;
[4-Carbamoyl-3-(4-hydroxy-cyclohexylamino)-phenyl]-(3,4,5-trimethoxy-phenyl)-acetic acid
2-(2-Methoxy-1-methyl-ethylamino)-4-(3,4,5-trimethoxy-phenylamino)-benzonitrile;
2-(2-Methoxy-1-methyl-ethylamino)-4-(3,4,5-trimethoxy-phenylamino)-benzamide; or
pharmaceutically acceptable salts thereof.
48 . A compound according to claim 1 , which is
4-(2-methoxyethylamino)-6-(3,4,5-trimethoxyphenylamino)nicotinonitrile;
4-(2-methoxyethylamino)-6-(3,4,5-trimethoxyphenylamino)nicotinamide;
3-(allylamino)-5-(4-iodo-3-methoxycyclohexa-1,4,5-trienylthio)picolinonitrile;
3-(allylamino)-5-(4-iodo-3-methoxycyclohexa-1,4,5-trienylthio)picolinamide;
5-(3,4-dimethoxybenzyl)-3-(tetrahydrofuran-3-ylamino)picolinonitrile;
5-(3,4-dimethoxybenzyl)-3-(tetrahydrofuran-3-ylamino)picolinamide;
5-(3-acetyl-4-methoxyphenyl)-3-(1-hydroxypropan-2-ylamino)picolinonitrile;
5-(3-acetyl-4-methoxyphenyl)-3-(1-hydroxypropan-2-ylamino)picolinamide;
4-(3,4-dimethoxyphenylamino)-2-(2-methoxyethoxy)benzonitrile;
4-(3,4-dimethoxyphenylamino)-2-(2-methoxyethoxy)benzamide;
2-(butylthio)-4-(3-iodo-4,5-dimethoxybenzyl)benzonitrile;
2-(butylthio)-4-(3-iodo-4,5-dimethoxybenzyl)benzamide;
4-(3-iodo-4,5-dimethoxyphenylthio)-3-(pentyloxy)benzonitrile;
4-(3-iodo-4,5-dimethoxyphenylthio)-3-(pentyloxy)benzamide;
2-bromo-4-(3-iodo-4,5-dimethoxybenzyl)benzonitrile;
2-bromo-4-(3-iodo-4,5-dimethoxybenzyl)benzamide;
3-chloro-4-(3-iodo-4,5-dimethoxyphenylthio)benzonitrile;
3-chloro-4-(3-iodo-4,5-dimethoxyphenylthio)benzamide;
2-(ethylamino)-3′-(methylsulfonyl)biphenyl-4-carboxamide;
2-(ethylamino)-3′-(methylsulfonyl)biphenyl-4-carboxamide;
2-fluoro-3′-(methylsulfonyl)biphenyl-4-carboxamide;
2-fluoro-3′-(methylsulfonyl)biphenyl-4-carboxamide;
2-bromo-4-(3,4-dimethoxy-5-methylphenylthio)benzamide;
2-bromo-4-(3,4-dimethoxy-5-methylphenylthio)benzamide;
2-fluoro-4-(3,4,5-trimethoxyphenylamino)benzamide;
2-fluoro-4-(3,4,5-trimethoxyphenylamino)benzamide;
3-fluoro-2′,3′-dimethoxybiphenyl-4-carboxamide;
3-fluoro-2′,3′-dimethoxybiphenyl-4-carboxamide;
4-(ethyl(3,4,5-trimethoxyphenyl)amino)-2-(2-methoxyethylamino)benzonitrile;
4-(ethyl(3,4,5-trimethoxyphenyl)amino)-2-(2-methoxyethylamino)benzamide;
2-(2-methoxyethylamino)-4-(1-(3,4,5-trimethoxyphenyl)propyl)benzonitrile;
2-(2-methoxyethylamino)-4-(1-(3,4,5-trimethoxyphenyl)propyl)benzamide;
2-(2-methoxyethylamino)-4-(3,4,5-trimethoxyphenylsulfinyl)benzonitrile;
2-(2-methoxyethylamino)-4-(3,4,5-trimethoxyphenylsulfinyl)benzamide;
2-(2-methoxyethylamino)-4-(3,4,5-trimethoxyphenylsulfonyl)benzonitrile;
2-(2-methoxyethylamino)-4-(3,4,5-trimethoxyphenylsulfonyl)benzamide;
2-[(1-oxidotetrahydro-2H-thiopyran-4-yl)amino]-4-[(3,4,5-trimethoxyphenyl)thio]benzonitrile;
2-[(1-oxidotetrahydro-2H-thiopyran-4-yl)amino]-4-[(3,4,5-trimethoxyphenyl)thio]benzamide;
2-(2-hydroxycyclohexylamino)-4-(3,4,5-trimethoxyphenylthio)benzonitrile;
2-(2-hydroxycyclohexylamino)-4-(3,4,5-trimethoxyphenylthio)benzamide;
2-(2-hydroxycyclopentylamino)-4-(3,4,5-trimethoxyphenylthio)benzonitrile;
2-(2-hydroxycyclopentylamino)-4-(3,4,5-trimethoxyphenylthio)benzamide;
4-(2-cyano-5-(3,4,5-trimethoxyphenylthio)phenylamino)cyclohexyl 2-aminoacetate;
4-(2-carbamoyl-5-(3,4,5-trimethoxyphenylthio)phenylamino)cyclohexyl 2-aminoacetate;
4-(3-iodo-4,5-dimethoxyphenylthio)-2-(tetrahydro-2H-pyran-4-ylamino)benzonitrile;
4-(3-iodo-4,5-dimethoxyphenylthio)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide;
4-(3,4-dimethoxy-5-methylphenylthio)-2-(tetrahydro-2H-pyran-4-ylamino)benzonitrile;
4-(3,4-dimethoxy-5-methylphenylthio)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide;
2-(tetrahydro-2H-pyran-4-ylamino)-4-(3,4,5-trimethoxyphenylamino)benzonitrile;
2-(tetrahydro-2H-pyran-4-ylamino)-4-(3,4,5-trimethoxyphenylamino)benzamide;
2-(4-hydroxycyclohexylamino)-4-(3,4,5-trimethoxyphenylamino)benzonitrile;
2-(4-hydroxycyclohexylamino)-4-(3,4,5-trimethoxyphenylamino)benzamide;
2-(tetrahydro-2H-thiopyran-4-ylamino)-4-(3,4,5-trimethoxyphenylamino)benzonitrile;
2-(tetrahydro-2H-thiopyran-4-ylamino)-4-(3,4,5-trimethoxyphenylamino)benzamide;
2-(1-isobutylpiperidin-4-ylamino)-4-(3,4,5-trimethoxyphenylamino)benzonitrile;
2-(1-isobutylpiperidin-4-ylamino)-4-(3,4,5-trimethoxyphenylamino)benzamide;
4-(3,4-dimethoxy-5-methylphenylamino)-2-(2-hydroxyethylamino)benzonitrile;
4-(3,4-dimethoxy-5-methylphenylamino)-2-(2-hydroxyethylamino)benzamide;
2-(2-hydroxyethylamino)-4-(3-iodo-4,5-dimethoxyphenylamino)benzonitrile;
2-(2-hydroxyethylamino)-4-(3-iodo-4,5-dimethoxyphenylamino)benzamide;
4-(2-chloro-3,4,5-trimethoxyphenylamino)-2-(2-hydroxyethylamino)benzonitrile;
4-(2-chloro-3,4,5-trimethoxyphenylamino)-2-(2-hydroxyethylamino)benzamide;
2-(tetrahydro-2H-pyran-4-ylamino)-4-(3,4,5-trimethoxybenzyl)benzonitrile;
2-(tetrahydro-2H-pyran-4-ylamino)-4-(3,4,5-trimethoxybenzyl)benzamide;
2-(4-aminocyclohexylamino)-4-(3,4,5-trimethoxybenzyl)benzonitrile;
2-(4-aminocyclohexylamino)-4-(3,4,5-trimethoxybenzyl)benzamide;
2-(2-oxocyclohexylamino)-4-(3,4,5-trimethoxybenzyl)benzonitrile;
2-(2-oxocyclohexylamino)-4-(3,4,5-trimethoxybenzyl)benzamide;
2-(3-(diethylamino)propylamino)-4-(3,4,5-trimethoxybenzyl)benzonitrile;
2-(3-(diethylamino)propylamino)-4-(3,4,5-trimethoxybenzyl)benzamide;
4-(3,4-dimethoxy-5-methylbenzyl)-2-(4-hydroxycyclohexylamino)benzonitrile;
4-(3,4-dimethoxy-5-methylbenzyl)-2-(4-hydroxycyclohexylamino)benzamide;
2-(4-hydroxycyclohexylamino)-4-(3-iodo-4,5-dimethoxybenzyl)benzonitrile;
2-(4-hydroxycyclohexylamino)-4-(3-iodo-4,5-dimethoxybenzyl)benzamide;
3-(4-hydroxycyclohexylamino)-3′-methoxybiphenyl-4-carbonitrile;
3-(4-hydroxycyclohexylamino)-3′-methoxybiphenyl-4-carboxamide;
4′-acetyl-3-(4-hydroxycyclohexylamino)-3′-methoxybiphenyl-4-carbonitrile;
4′-acetyl-3-(4-hydroxycyclohexylamino)-3′-methoxybiphenyl-4-carboxamide;
4′-acetyl-3-(4-hydroxycyclohexylamino)biphenyl-4-carbonitrile;
4′-acetyl-3-(4-hydroxycyclohexylamino)biphenyl-4-carboxamide;
3-(4-hydroxycyclohexylamino)-4′-(methylsulfinyl)biphenyl-4-carbonitrile;
3-(4-hydroxycyclohexylamino)-4′-(methylsulfinyl)biphenyl-4-carboxamide;
3-(4-hydroxycyclohexylamino)-41-(methylthio)biphenyl-4-carbonitrile;
3-(4-hydroxycyclohexylamino)-4′-(methylthio)biphenyl-4-carboxamide;
3-(4-hydroxycyclohexylamino)-3′,4′,5′-trimethoxybiphenyl-4-carbonitrile;
3-(4-hydroxycyclohexylamino)-3′,4′,5′-trimethoxybiphenyl-4-carboxamide;
3′,4′-difluoro-3-(4-hydroxycyclohexylamino)biphenyl-4-carbonitrile;
3′,4′-difluoro-3-(4-hydroxycyclohexylamino)biphenyl-4-carboxamide;
3-(4-hydroxycyclohexylamino)-4′-nitrobiphenyl-4-carbonitrile;
3-(4-hydroxycyclohexylamino)-4′-nitrobiphenyl-4-carboxamide;
4′-amino-3-(4-hydroxycyclohexylamino)biphenyl-4-carbonitrile;
4′-amino-3-(4-hydroxycyclohexylamino)biphenyl-4-carboxamide;
3′-ethynyl-3-(4-hydroxycyclohexylamino)biphenyl-4-carbonitrile;
3′-ethynyl-3-(4-hydroxycyclohexylamino)biphenyl-4-carboxamide; or
pharmaceutically acceptable salts thereof.
49 . A pharmaceutical composition comprising at least one compound or salt according to claim 1 and a pharmaceutically acceptable solvent, carrier, excipient, adjuvant or a combination thereof.
50 . A method of treating cancer, inflammation, or arthritis comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound or salt of claim 1 .
51 . A method for treating a subject suffering from a disease or disorder of proteins that are either client proteins for HSP-90 or indirectly affect its client proteins, wherein disorder is selected from the group of inflammatory diseases, infections, autoimmune disorders, stroke, ischemia, cardiac disorders, neurological disorders, fibrogenetic disorders, proliferative disorders, tumors, leukemias, neoplasms, cancers, carcinomas, metabolic diseases, malignant disease, scleroderma, polymyositis, systemic lupus, rheumatoid arthritis, liver cirrhosis, keloid formation, interstitial nephritis, pulmonary fibrosis, and sepsis, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound or salt of claim 1 .
52 . A method of reducing the level of infection in a subject where the infection is caused by an organism selected from Plasmodium species, the method comprising administering to an infected subject an effective amount of a compound or salt according to claim 1 .
53 . A method for treating a fungal infection in a patient in need of such treatment, comprising administering an effective amount of a compound or salt according to claim 1 and an optional anti-fungal agent or drug.
54 . A method according to claim 50 , for the treatment of cancer and further comprising administration of (a) at least one additional anti-cancer agent or composition or (b) radiation therapy.
55 . A method of treating a patient suffering from a viral infection comprising administering to the patient a therapeutically effective amount of a compound of claim 1.